Abliva
Develops medicines for the treatment of primary mitochondrial diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| SEK | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 61 % | (30 %) | (79 %) | 342 % | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (55777 %) | (26640 %) | (79946 %) | (258671 %) | (62080 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (57458 %) | (27773 %) | (81783 %) | (275039 %) | (69715 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | 189948 % | 39152 % | - |
Source: Company filings or news article
Related Content
Abliva focuses on developing therapeutics for mitochondrial diseases, which are rare and severe conditions caused by dysfunctional mitochondria, the cell's energy providers. The company operates in the biopharmaceutical sector, targeting orphan indications with high unmet medical needs. Abliva's business model involves advancing a portfolio of projects from early discovery to clinical phases, aiming to bring effective treatments to market. Revenue generation is anticipated through the successful development and commercialization of these medicines, potentially benefiting from orphan drug designations that offer market exclusivity. The company serves patients with mitochondrial diseases, a niche market with significant demand for effective therapies.
Keywords: mitochondrial, medicine, therapeutics, orphan, disease, biopharmaceutical, clinical, discovery, treatment, revenue.
